<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002029</url>
  </required_header>
  <id_info>
    <org_study_id>041A</org_study_id>
    <nct_id>NCT00002029</nct_id>
  </id_info>
  <brief_title>Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent</brief_title>
  <official_title>Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      To compare two lipid emulsions in the long-term parenteral alimentation of patients with AIDS
      in relation to: Clinical effectiveness. Effect on immunologic function. Effect on HIV load as
      measured by p24 antigen levels. Effect on relative HIV infectivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fat Emulsion 2%</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fat Emulsion 20%</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Zidovudine (AZT).

          -  All drugs used for the standard treatment of opportunistic infections.

          -  Other drugs used for the treatment of other AIDS conditions if they have been started
             more than 3 months prior to study entry.

        Patients must have:

          -  Diagnosis of AIDS.

          -  Weight loss of &gt; 10 percent premorbid body weight.

          -  Presenting diagnosis of either opportunistic infection or Kaposi's sarcoma.

          -  Require home total parenteral nutrition (TPN) for a period of approximately 3 months.

          -  Life expectancy = or &gt; 90 days.

        Prior Medication:

        Allowed:

          -  Zidovudine (AZT).

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Life expectancy &lt; 90 days.

          -  Biliary stasis.

          -  History of drug abuse.

        Patients with the following are excluded:

          -  Life expectancy &lt; 90 days.

          -  Biliary stasis.

          -  History of drug abuse.

        Prior Medication:

        Excluded within 3 months of study entry:

          -  Immunomodulators.

          -  Experimental antiviral DT. History of drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Intracare Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Orange Veterans Administration Med Ctr</name>
      <address>
        <city>East Orange</city>
        <state>New Jersey</state>
        <zip>07018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Singer P, Rubinstein A, Askanazi J, Calvelli T, Lazarus T, Kirvel√§ O, Katz DP. Clinical and immunologic effects of lipid-based parenteral nutrition in AIDS. JPEN J Parenter Enteral Nutr. 1992 Mar-Apr;16(2):165-7.</citation>
    <PMID>1556814</PMID>
  </reference>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>February 19, 2009</last_update_submitted>
  <last_update_submitted_qc>February 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2009</last_update_posted>
  <keyword>Weight Loss</keyword>
  <keyword>Parenteral Nutrition, Total</keyword>
  <keyword>AIDS-Related Opportunistic Infections</keyword>
  <keyword>Liposyn</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
    <mesh_term>Safflower oil, soybean oil, lecithin emulsion</mesh_term>
    <mesh_term>Safflower oil, soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

